Here are the top 5 biosimilar articles for the week of August 10, 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of August 10, 2020.
5. Sandoz Rituximab Measures Up in DLBCL
Number 5: A rituximab biosimilar in diffuse large B-cell lymphoma (DLBCL) passes the real-world test with flying colors, according to Manfred Weslau, MD.
4. Samsung Bioepis Enters Breast and Gastric Market in Brazil
Number 4: Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.
3. Samsung Bioepis Appeals to Patients Through Package Design
Number 3: In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.
2. Anti-TNF Biologics Outperform in Crohn Disease
Number 2: A real-world study on inflammatory bowel disease employing originator and biosimilar biologics suggests anti—tumor necrosis factor (TNF) therapy may be more effective for Crohn disease than for ulcerative colitis.
1. Cadila Puts a Teriparatide Biosimilar on the Market
Number 1: Cadila Pharmaceuticals charges ahead with yet another biosimilar launch in India, an osteoporosis agent referencing Eli Lilly's teriparatide drug Forteo.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.